CRAD001m2304 "Three-armed, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of two ranges of everolimus minimum Concentrations as adjuvant therapy in patients with tuberous sclerosis complex (TSC) with partial seizures Refractory to treatment.